Ulf Mark Schneider (born 1965) is the current CEO of Fresenius, a $21 billion global health care group.[1]
Schneider was born and raised in Germany and became a U.S. citizen in 2003. He holds a doctorate in economics from the University of St. Gallen, Switzerland, and an MBA from Harvard Business School.[2] Schneider joined Fresenius in November 2001 and served as Chief Financial Officer of Fresenius Medical Care before assuming his current position in May, 2003. Previously, he was Group Finance Director for Gehe UK plc., a pharmaceutical wholesale and retail distributor, in Coventry, England. Schneider held several senior executive positions since 1989 with Gehe’s majority shareholder, Franz Haniel & Cie. GmbH, a diversified German industrial company.[3] Under his leadership, Fresenius has more than doubled its revenues and increased net income nearly sixfold. The management challenges of global growth and future strategies in the health care and pharmaceutical industries are of particular interest to Schneider.[4][5][6]
Schneider serves on the board of Bürgerhospital Frankfurt, a not-for profit hospital in Frankfurt/Germany, and chairs the European Advisory Board of Harvard Business School.